The UK government has committed £650,000 to launch the Scotland CardioMetabolic Impact Study (SCoMIS), a landmark research initiative designed to evaluate the real-world effectiveness of weight-loss medicines in Scotland's most economically disadvantaged communities. The study will recruit 3,000 to 5,000 participants from across Scotland, with full implementation scheduled for 2026.
The collaborative effort brings together industry leaders Novo Nordisk and IQVIA with academic institutions including the Universities of Glasgow, Dundee, and Edinburgh. The current funding will support the research design phase, with additional funding potentially available through 2029-2030 subject to approvals.
Addressing Health Inequalities Through Targeted Research
More than one in three adults in Scotland's most deprived areas are living with obesity, according to UK Health Innovation Minister Dr Zubir Ahmed. The study specifically targets these communities to address growing health inequalities and ensure that innovative treatments reach those who need them most.
"The burden of obesity is greatest in the most deprived segments of society and the status quo risks widening health inequalities," said Professor Jason Gill, lead of the SCoMIS consortium and Professor of CardioMetabolic Health at the University of Glasgow. "SCoMIS aims to be a landmark real-world study evaluating a new model of obesity care, providing incretin treatment via primary and community care to Scottish adults living with obesity, with a focus on those in the most economically deprived communities."
Focus on GLP-1 Incretin-Based Therapies
The study will specifically examine incretin-based weight loss medicines (GLP-1), which copy or boost the effects of natural hormones called incretins that control blood sugar levels. These medications act on brain areas that impact hunger and appetite and can slow gastric emptying, potentially helping people with obesity regulate their eating habits.
The research will investigate weight change patterns, detection and prevention of obesity-related complications, and overall safety and effectiveness of these treatments in real-world NHS settings. If successful, the findings will guide NHS commissioning decisions and BMI thresholds for incretin-based treatments.
Comprehensive Research Framework
The SCoMIS Main Study will address four critical research questions. First, it will test how weight-loss medicines can be delivered effectively and fairly in everyday NHS care. Second, it will measure weight loss levels and quality of life improvements, particularly for patients in disadvantaged areas. Third, it will examine the impact on obesity-related illness, NHS utilization, and overall healthcare costs. Finally, it will explore whether improved health through weight loss can help people maintain employment, reduce sick leave, and participate more fully in society.
The research design phase will establish the study protocol, confirm patient recruitment methods, and ensure the main study is practical, equitable, and ready for large-scale implementation.
Technology Integration and Patient Support
IQVIA will contribute AI-driven digital technologies to support patient access, engagement, and data collection throughout the study. "SCoMIS aims to demonstrate, through advanced real-world evidence, how expedited access to innovative medicines—combined with IQVIA AI driven digital patient support—will build capacity in primary care and improve outcomes for patients, whilst driving economic growth," said Tim Sheppard, Senior Vice President North Europe and UK GM for IQVIA.
Clinical and Economic Implications
Professor Naveed Sattar, Chair of the UK Obesity Healthcare Goals Programme, emphasized the study's significance: "Obesity has become the most pressing challenge in modern medicine. The growing recognition of the need for more clinical trials - designed to assess both the benefits and safety of new treatments in the communities most affected - is a hugely welcome and necessary step forward."
The research is positioned within the UK government's broader Obesity Healthcare Goals programme, which aims to transform the lives of the one in three Britons affected by obesity. As a leading cause of long-term illnesses including heart disease and cancer, tackling obesity could potentially save the NHS billions annually while helping millions live longer, healthier lives.
The study represents a significant investment in addressing health inequalities while positioning the UK as a global leader in obesity research and treatment innovation. The collaborative approach between government, industry, and academia demonstrates the potential for comprehensive solutions to complex public health challenges.
